News

The company received series E financing, which was supported by existing investors such as dievini Hopp Biotech, Wellington Partners and AT Impf GmbH, as well as by new

Jenner Institute of Oxford University and Vaccitech, which was spun out of it, had developed the new flu vaccine. Over 10,000 people aged 65 and over will be

The latest agreement with Bayer extends their access to X-Chem’s DEX™ technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs.

On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a determining marker of Hodgkin lymphoma. The ADC includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to

An anti-von Willebrand factor (vWF) nanobody, Caplacizumab met both the primary endpoint and key secondary endpoints of the phase 3 trial, dubbed HERCULES. The late-stage trial evaluated it against

Endocyte intends to move quickly into Phase 3 development of 1 Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of

Hundreds of thousands of Americans could be protected from or treated for Ebola infections through the first purchase of vaccines and therapeutic drugs by the Biomedical Advanced Research

The FDA’s decision on approval is anticipated to be taken by 28 January 2018. Roche’s supplemental Biologics License Application (sBLA), which was accepted by the FDA, is based